The primary mission of Core A is to provide leadership, coordination and integration of all the components of the UK-ADC, so that our programmatic and scientific goals are achieved. Our overall scientific objective is to support and facilitate research aimed at elucidating the pathogenic mechanisms underlying the transitions from normal cognitive aging to the development of AD, with a long-term goal of enabling more effective translation of this mechanistic knowledge to intervention strategies. The UK-ADC has historically been at the forefront of supporting research in identification of the early manifestations of disease and the pathogenic mechanisms underlying the transitions from normal cognitive aging to the development of AD. In the renewal period, we will build upon this highly successful focus, as well as leverage several recent positive developments at UK that will expand our translational research capability, and thereby help to increase the rate of progress toward new therapies to delay or prevent AD. The UK-ADC functions in a multidisciplinary, integrated, and supportive environment that catalyzes high-quality AD research within the UK community and throughout Kentucky and beyond. The ADC also enhances education and outreach within UK and in the community, and provides clinical diagnoses and care of patients with cognitive impairment. The ADC serves as the focal point of all AD-related activities in Kentucky, providing the infrastructure and resources to enhance scientific interactions and develop new collaborations. The ADC also reaches beyond Kentucky to enhance AD research, education, and clinical practice on a national level through its interactions with other ADCs, as well as other regional and national institutions, including the Alzheimer's Association, NIA and industry. An effective Administrative Core is essential for transforming ADC goals into accomplishments. Therefore, Core A will continue to support the ability of our UK-ADC to serve as a critical resource for the university, community, state, region and nation through a set of integrated and intertwined specific aims.
Aim 1 : Provide leadership and an organizational framework for management and coordination of all ADC activities to ensure optimal resource utilization to meet the overall goals of the ADC.
Aim 2 : Enable the ADC to serve as the focal point of AD-related activities in Kentucky by continuing to coordinate, facilitate, and promote scientific interactions.
Aim 3 : Contribute to and interact with other ADCs and other national collaborative activities and the lay community, to increase visibility of the ADC and maximize progress in AD research throughout the country.
Our goal is to catalyze outstanding AD research while ensuring more rapid progress toward new therapies to delay or prevent AD, so that our human volunteers, patients and caregivers become the beneficiaries of our advances in knowledge. Our well integrated center is moving the field of cognitive aging and AD forward and supporting the elucidation of mechanisms of disease progression so that successful interventions can be developed in the future to treat or prevent this most dehumanizing disorder to affect humans.
|Bardach, Shoshana H; Holmes, Sarah D; Jicha, Gregory A (2018) Motivators for Alzheimer's disease clinical trial participation. Aging Clin Exp Res 30:209-212|
|Bardach, Shoshana H; Schoenberg, Nancy E (2018) The Role of Primary Care Providers in Encouraging Older Patients to Change Their Lifestyle Behaviors. Clin Gerontol 41:326-334|
|Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10|
|Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600|
|Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71|
|Zhou, Zilu; Wang, Weixin; Wang, Li-San et al. (2018) Integrative DNA copy number detection and genotyping from sequencing and array-based platforms. Bioinformatics 34:2349-2355|
|Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25|
|Barber, Justin M; Bardach, Shoshana H; Jicha, Gregory A (2018) Alzheimer Disease Clinical Trial Recruitment: Does Participation in a Brief Cognitive Screen at a Community Health Fair Promote Research Engagement? Alzheimer Dis Assoc Disord 32:333-338|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
Showing the most recent 10 out of 471 publications